The excellent in vitro and in vivo efficacy of Cpd17 in liver disease models, together with GLPG1690 efficacy in treating IPF, argue that Type IV compounds are very promising agents in treating fibrotic diseases and possibly other pathologies related to the LPA/ATX axis. Here, LPA is linked to liver disorder.